AcelRx Pharmaceuticals Company Profile (NASDAQ:ACRX)

About AcelRx Pharmaceuticals (NASDAQ:ACRX)

AcelRx Pharmaceuticals logoAcelRx Pharmaceuticals, Inc. is a pharmaceutical company focused on the development and commercialization of therapies for the treatment of moderate-to-severe acute pain. The Company operates through the segment, which includes development and commercialization of product candidates for the treatment of pain. Its lead product candidates include ARX-04, Zalviso, which utilize sublingual sufentanil, delivered through a non-invasive route of administration, and ARX-03. ARX-04 is meant for the treatment of moderate-to-severe acute pain to be administered by a healthcare professional to a patient in medically supervised settings. Zalviso is meant for the management of moderate-to-severe acute pain in hospitalized adult patients. ARX-03 provides mild sedation, anxiety reduction and pain relief for patients undergoing painful procedures in a physician's office. It also includes ARX-02, which is meant for the treatment of patients who suffer from breakthrough pain (BTP) due to cancer.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: N/A
  • Symbol: NASDAQ:ACRX
  • CUSIP: N/A
  • Web:
  • Market Cap: $91.89 million
  • Outstanding Shares: 45,380,000
Average Prices:
  • 50 Day Moving Avg: $3.55
  • 200 Day Moving Avg: $2.92
  • 52 Week Range: $1.55 - $5.75
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -2.15
  • P/E Growth: 0.000
Sales & Book Value:
  • Annual Revenue: $15.57 million
  • Price / Sales: 5.90
  • Book Value: ($0.70) per share
  • Price / Book: -2.91
  • EBITDA: ($35,160,000.00)
  • Net Margins: -319.19%
  • Return on Assets: -53.35%
  • Debt-to-Equity Ratio: -0.47%
  • Current Ratio: 4.92%
  • Quick Ratio: 4.81%
  • Average Volume: 2.26 million shs.
  • Beta: 3.04
  • Short Ratio: 2.51

Frequently Asked Questions for AcelRx Pharmaceuticals (NASDAQ:ACRX)

What is AcelRx Pharmaceuticals' stock symbol?

AcelRx Pharmaceuticals trades on the NASDAQ under the ticker symbol "ACRX."

How were AcelRx Pharmaceuticals' earnings last quarter?

AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) issued its quarterly earnings data on Tuesday, August, 1st. The company reported ($0.29) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.28) by $0.01. The firm had revenue of $2.66 million for the quarter, compared to analyst estimates of $2.63 million. View AcelRx Pharmaceuticals' Earnings History.

When will AcelRx Pharmaceuticals make its next earnings announcement?

AcelRx Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Monday, October, 30th 2017. View Earnings Estimates for AcelRx Pharmaceuticals.

Where is AcelRx Pharmaceuticals' stock going? Where will AcelRx Pharmaceuticals' stock price be in 2017?

7 equities research analysts have issued twelve-month price targets for AcelRx Pharmaceuticals' shares. Their forecasts range from $2.00 to $14.00. On average, they anticipate AcelRx Pharmaceuticals' share price to reach $7.67 in the next twelve months. View Analyst Ratings for AcelRx Pharmaceuticals.

What are analysts saying about AcelRx Pharmaceuticals stock?

Here are some recent quotes from research analysts about AcelRx Pharmaceuticals stock:

  • 1. According to Zacks Investment Research, "AcelRx Pharmaceuticals, Inc., is a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of pain. The Company product candidates comprises: ARX-01 or the Sufentanil NanoTab PCA System; ARX-02 or the Sufentanil NanoTab BTP Management System; and ARX-03 or the Sufentanil/Triazolam NanoTab which are in their development stage. Its product ARX-01 is focused on acute post-operative pain, ARX-02 is focused on the treatment of cancer breakthrough pain and ARX-03 is focused on providing mild sedation, anxiety reduction, and pain relief to patients undergoing painful procedures in a physician's office. AcelRx Pharmaceuticals, Inc. is headquartered in Redwood City, California. " (8/4/2017)
  • 2. Stifel Nicolaus analysts commented, "Arc Logistics Partners LP reported 4Q16 Adjusted EBITDA of $13.9 million, below our estimate of $14.9 million, and distributable cash flow (DCF) of $11.0 million against our estimate of $11.1 million. Adjusted EBITDA came in below our estimates due to slightly lower revenues and higher operating expense on the quarter. Management provided an update on the ongoing Gulf LNG arbitration case and noted that the arbitration panel has heard the arguments and is in the process of rendering a decision. With that said, a timeline for a decision was not provided. On the call management highlighted their belief that the Gulf arbitration is acting as an overhang on ARCX units and expect a resolution to provide uplift to the partnership's valuation (assuming a positive outcome). Although we ultimately expect a favorable resolution for ARCX in the Gulf LNG arbitration, a full valuation and uncertainty over the outcome are keeping us on the sidelines. At this time we are maintaining our Hold rating." (3/14/2017)
  • 3. Royal Bank Of Canada analysts commented, "ACRX reported 4Q results after the close where focus was primarily on the upcoming DSUVIA (ARX-04) launch, the expected AdCom meeting prior to approval, and progress with the Zalviso trial and the EU launch. We continue to view the story as on-track and make only minor adjustments to our model. We reiterate our Outperform rating and $6 PT." (3/3/2017)

Who are some of AcelRx Pharmaceuticals' key competitors?

Who are AcelRx Pharmaceuticals' key executives?

AcelRx Pharmaceuticals' management team includes the folowing people:

  • Adrian Adams, Independent Chairman of the Board
  • Richard A. King, President
  • Vincent J. Angotti, Chief Executive Officer
  • Raffi M. Asadorian, Chief Financial Officer
  • Pamela P. Palmer M.D. Ph.D., Chief Medical Officer, Director
  • Badri N. Dasu, Chief Engineering Officer
  • Lawrence G. Hamel, Chief Development Officer
  • Jane Wright-Mitchell, Chief Legal Officer
  • Richard F. Afable M.D., Director
  • Howard B. Rosen, Director

How do I buy AcelRx Pharmaceuticals stock?

Shares of AcelRx Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is AcelRx Pharmaceuticals' stock price today?

One share of AcelRx Pharmaceuticals stock can currently be purchased for approximately $2.03.

MarketBeat Community Rating for AcelRx Pharmaceuticals (NASDAQ ACRX)
Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  244 (Vote Outperform)
Underperform Votes:  167 (Vote Underperform)
Total Votes:  411
MarketBeat's community ratings are surveys of what our community members think about AcelRx Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for AcelRx Pharmaceuticals (NASDAQ:ACRX) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 3 Hold Ratings, 4 Buy Ratings
Consensus Rating:Buy (Score: 2.57)
Consensus Price Target: $7.67 (278.60% upside)
Consensus Price Target History for AcelRx Pharmaceuticals (NASDAQ:ACRX)
Price Target History for AcelRx Pharmaceuticals (NASDAQ:ACRX)
Analysts' Ratings History for AcelRx Pharmaceuticals (NASDAQ:ACRX)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
10/13/2017Piper Jaffray CompaniesReiterated RatingHold$2.00N/AView Rating Details
10/13/2017Royal Bank Of CanadaLower Price TargetOutperform -> Outperform$6.00 -> $5.00N/AView Rating Details
10/13/2017Jefferies Group LLCDowngradeBuy -> HoldN/AView Rating Details
10/12/2017Roth CapitalSet Price TargetBuy$8.00N/AView Rating Details
10/3/2017HC WainwrightReiterated RatingBuy$10.00HighView Rating Details
8/9/2017Stifel NicolausUpgradeHold -> BuyHighView Rating Details
8/1/2017Cowen and CompanyReiterated RatingHoldHighView Rating Details
5/6/2016Seaport Global SecuritiesUpgradeAccumulate -> BuyN/AView Rating Details
4/14/2016Janney Montgomery ScottInitiated CoverageNeutralN/AView Rating Details
(Data available from 10/23/2015 forward)


Earnings History for AcelRx Pharmaceuticals (NASDAQ:ACRX)
Earnings by Quarter for AcelRx Pharmaceuticals (NASDAQ:ACRX)
Earnings History by Quarter for AcelRx Pharmaceuticals (NASDAQ ACRX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
10/30/2017($0.28)N/AView Earnings Details
8/1/2017Q2 2017($0.28)($0.29)$2.63 million$2.66 millionViewListenView Earnings Details
5/8/2017Q1 2017($0.28)($0.34)$2.36 million$3.11 millionViewListenView Earnings Details
3/2/2017Q4 2016($0.23)($0.21)$3.05 million$6.44 millionViewListenView Earnings Details
11/1/2016Q316($0.23)($0.25)$2.89 million$1.60 millionViewN/AView Earnings Details
7/28/2016Q216($0.22)($0.24)$2.17 million$4.53 millionViewListenView Earnings Details
3/7/2016Q415($0.10)($0.24)$4.97 million$1.73 millionViewListenView Earnings Details
10/29/2015Q315($0.23)$0.11$1.75 million$13.90 millionViewListenView Earnings Details
8/3/2015Q215($0.26)($0.20)$0.30 million$1.92 millionViewListenView Earnings Details
5/4/2015Q115($0.28)($0.27)$0.40 million$0.18 millionViewN/AView Earnings Details
11/10/2014Q4 2014($0.33)($0.32)$4.95 million$4.83 millionViewN/AView Earnings Details
8/11/2014Q214($0.27)($0.34)$0.20 million$0.07 millionViewN/AView Earnings Details
5/8/2014Q114($0.23)($0.22)$0.28 million$0.10 millionViewN/AView Earnings Details
3/3/2014Q413($0.17)($0.18)$4.93 million$27.60 millionViewN/AView Earnings Details
11/5/2013Q313($0.19)($0.26)ViewN/AView Earnings Details
8/12/2013Q2 2013($0.22)($0.22)$1.73 million$0.41 millionViewListenView Earnings Details
11/6/2012Q312($0.38)($0.38)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for AcelRx Pharmaceuticals (NASDAQ:ACRX)
2017 EPS Consensus Estimate: ($0.91)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.21)($0.21)($0.21)
Q2 20171($0.22)($0.22)($0.22)
Q3 20172($0.24)($0.23)($0.24)
Q4 20172($0.29)($0.19)($0.24)
(Data provided by Zacks Investment Research)


Dividend History for AcelRx Pharmaceuticals (NASDAQ:ACRX)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for AcelRx Pharmaceuticals (NASDAQ:ACRX)
Insider Ownership Percentage: 28.10%
Institutional Ownership Percentage: 23.32%
Insider Trades by Quarter for AcelRx Pharmaceuticals (NASDAQ:ACRX)
Institutional Ownership by Quarter for AcelRx Pharmaceuticals (NASDAQ:ACRX)
Insider Trades by Quarter for AcelRx Pharmaceuticals (NASDAQ:ACRX)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
10/2/2017Lawrence G HamelInsiderSell10,161$5.29$53,751.69View SEC Filing  
9/11/2017Raffi AsadorianCFOBuy7,000$3.24$22,680.00View SEC Filing  
8/24/2017Mark G EdwardsDirectorBuy5,000$3.02$15,100.00View SEC Filing  
8/24/2017Vincent J AngottiCEOBuy15,000$3.00$45,000.00View SEC Filing  
8/22/2017Pamela P. PalmerInsiderBuy10,000$2.95$29,500.00View SEC Filing  
6/19/2017Life Sciences Maste PerceptiveMajor ShareholderSell875,000$2.40$2,100,000.00View SEC Filing  
9/29/2016Perceptive Advisors LlcMajor ShareholderSell216,500$3.92$848,680.00View SEC Filing  
9/15/2016Perceptive Advisors LlcMajor ShareholderSell392,850$3.70$1,453,545.00View SEC Filing  
5/13/2016Howard B RosenCEOBuy10,206$3.26$33,271.56View SEC Filing  
5/12/2016Mark G EdwardsDirectorBuy15,000$3.15$47,250.00View SEC Filing  
11/18/2015Perceptive Advisors LlcMajor ShareholderSell176,200$5.35$942,670.00View SEC Filing  
11/6/2015Perceptive Advisors LlcMajor ShareholderSell92,100$4.59$422,739.00View SEC Filing  
9/9/2015Perceptive Advisors LlcMajor ShareholderSell310,000$4.18$1,295,800.00View SEC Filing  
5/7/2015Mark G EdwardsDirectorBuy40,000$3.13$125,200.00View SEC Filing  
3/10/2014Mark WanDirectorSell1,000,000$12.35$12,350,000.00View SEC Filing  
11/7/2013Perceptive Advisors Llcmajor shareholderBuy200,000$6.51$1,302,000.00View SEC Filing  
11/4/2013Perceptive Advisors Llcmajor shareholderBuy155,000$6.87$1,064,850.00View SEC Filing  
11/1/2013Perceptive Advisors LlcMajor ShareholderBuy360,660$6.91$2,492,160.60View SEC Filing  
9/20/2013Guy NohraDirectorSell158,153$10.59$1,674,840.27View SEC Filing  
9/18/2013Guy NohraDirectorSell128,780$10.42$1,341,887.60View SEC Filing  
7/23/2013Perceptive Advisors LlcMajor ShareholderBuy850,000$11.65$9,902,500.00View SEC Filing  
6/6/2013Mark G EdwardsDirectorBuy10,000$8.10$81,000.00View SEC Filing  
5/28/2013Adrian AdamsDirectorBuy75,000$8.19$614,250.00View SEC Filing  
12/7/2012Mark A WanDirectorBuy2,416,918$3.31$7,999,998.58View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for AcelRx Pharmaceuticals (NASDAQ:ACRX)
Latest Headlines for AcelRx Pharmaceuticals (NASDAQ:ACRX)
Loading headlines, please wait.



AcelRx Pharmaceuticals (ACRX) Chart for Monday, October, 23, 2017

This page was last updated on 10/23/2017 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.